
2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
The authors establish a quantitative framework for understanding the correlation between the segregation of pharmaceutical powders and various physical and process parameters.
over 22 years ago
Big Pharma Works on Productivityover 22 years ago
Hyperthermophilic Microorganisms and USP Hot Water Systemsover 22 years ago
Electronic Information Systemsover 22 years ago
CMO-grown Innovation and Technology





